Why Clearmind Medicine Stock Is Moving Higher
Why Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine Inc. (NASDAQ:CMND) shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.
Clearmind Medicine Inc.（納斯達克股票代碼：CMND）週二股價上漲，此前該公司宣佈與Yissum Research Development簽署了獨家專利許可協議。
What Happened: The agreement with Yissum Research Development grants Clearmind Medicine the exclusive right to develop, manufacture and commercialize compounds invented by professors Rami Yaka, Ahmend Masaewa and Avi Priel of the Hebrew University.
發生了什麼：與Yissum Research Development的協議授予Clearmind Medicine開發、製造和商業化希伯來大學教授拉米·亞卡、艾哈邁德·馬薩埃瓦和阿維·普里爾發明的化合物的專有權利。
These compounds will work to treat post-traumatic stress disorder (PTSD) along with other mental health conditions. Current treatment options provide limited relief and may cause other side effects, such as weight gain.
這些化合物將用於治療創傷後應激障礙（PTSD）以及其他心理健康狀況。目前的治療方案提供的緩解效果有限，並可能導致其他副作用，例如體重增加。
"We are excited to announce this groundbreaking patent license agreement, which reflects our strong collaboration with Yissum and the Hebrew University, a world-leading institution. This agreement marks a significant stride in our mission to meet urgent mental health care needs," said Dr. Adi Zullof-Shani, CEO of Clearmind Medicine.
“我們很高興地宣佈這項開創性的專利許可協議，這反映了我們與Yissum和世界領先機構希伯來大學的緊密合作。該協議標誌着我們在滿足緊急心理保健需求的使命方面取得了長足的進步。” Clearmind Medicine首席執行官阿迪·祖洛夫-沙尼博士說。
"We believe that the psychedelic compounds covered by this agreement hold immense promise in treating complex conditions like PTSD, offering a new ray of hope to millions of people worldwide."
“我們認爲，該協議所涵蓋的迷幻化合物在治療創傷後應激障礙等複雜疾病方面具有巨大的希望，爲全球數百萬人帶來了新的希望。”
Under terms of the agreement, Clearmind Medicine is eligible to receive future milestone payments, royalties on future sales and commitments to safeguard intellectual property rights.
根據協議條款，Clearmind Medicine有資格獲得未來的里程碑付款、未來銷售的特許權使用費和保護知識產權的承諾。
The 2023 global market value for PTSD treatment was $16.8 billion and it's expected to reach $27.37 billion by 2033.
2023年創傷後應激障礙治療的全球市值爲168億美元，預計到2033年將達到273.7億美元。
Related Link: 4 Analysts Have This To Say About Omega Therapeutics
相關鏈接：4位分析師對歐米茄療法有這樣的看法
CMND Price Action: Clearmind shares were trading 18.8% higher at $1.38 Tuesday morning, according to Benzinga Pro.
CMND價格走勢：根據Benzinga Pro的數據，週二上午Clearmind股價上漲18.8％，至1.38美元。
Image: Pixabay.
圖片：Pixabay。
譯文內容由第三人軟體翻譯。